Skip links

GSS EU Science Funding Gateway

Green pharmaceuticals

Summary

The Cluster Health is under Pillar 2 of Horizon Europe. Its role is to advance knowledge and capabilities, improve understanding of health and diseases, develop innovative methodological and technological solutions to better manage health and diseases, as well as to design sustainable approaches for the digital transformation and delivery of integrated, person-centred and equitable health and care services.

Programme Name

Horizon Europe (2021-2027)

Programme Description

Horizon Europe is the European Union (EU) funding programme for the period 2021 – 2027, which targets the sectors of research and innovation. The programme’s budget is around € 95.5 billion, of which € 5.4 billion is from NextGenerationEU to stimulate recovery and strengthen the EU’s resilience in the future, and € 4.5 billion is additional aid.

Programme Details

Call

Green pharmaceuticals

Detailed Call Description

The Purposes:

  • To encourage taking into account the environmental aspects of pharmaceuticals as regards their use and disposal. The action intends to promote the development of pharmaceuticals intrinsically less harmful to environment. The solid knowledge of the impact of molecules on the environment through the eco-toxicity studies will contribute to management of environmental risk and may be taken into account for designing of new molecules.
  • To promote the green innovation in the pharmaceutical manufacturing of marketed medicinal products, in particular manufacturing of their active pharmaceutical ingredients (APIs). It will contribute to ensuring supplies of medicinal products and prevent shortages as well as crisis preparedness. The difficulties in ensuring compliance with the high environmental standards in the EU and high costs of such compliance are considered one of the main reason for pharmaceutical manufacturing leaving the EU. This in turn results in vulnerabilities of the supply chains (reduced number of suppliers of critical inputs, lack of geographical diversification of the suppliers, lack of critical manufacturing capacity in the EU).

Applicants should propose activities linked to several of the following elements:

  • Research and innovation to support the development of “greener” pharmaceuticals that degrade more readily to harmless substances in waste water treatment plants and the environment;
  • Research on the eco-toxicity and environmental fate of pharmaceuticals, in particular those that are not yet subject to environmental risk assessment;
  • Propose innovative manufacturing technology that are greener, low in energy consumption and emissions, using less solvent or recycling solvents;
  • Propose methods for eliminating carcinogenic impurities in pharmaceuticals (e.g. nitrosamines) process and medicinal products, in particular as complementary technologies to the manufacturing methods relying on recycled solvents;
  • Explore innovative uses of digital transformation or robotic for competitive and scalable methods of production.

Projects should integrate at the same time the academic and public health perspective. Proposals could consider the involvement of the European Commission’s Joint Research Centre (JRC) in the field of new approach methodologies for ecotoxicity assessment.

Financing percentage by EU or other bodies / Level of Subsidy or Loan

100%

Contribution per project: € 8,00 million

Eligibility For Participation Notes

The Joint Research Centre (JRC) may participate as member of the consortium selected for funding.

Programme Category
EU Competitive Programmes
Total Budget
€ 40,00 million
Thematic Categories
  • Environment and Climate Change
  • Health
  • Research, Technological Development and Innovation
Eligibility for Participation
  • Central Government
  • Educational Institutions
  • NGOs
  • Non Profit Organisations
  • Private Bodies
  • Researchers/Research Centers/Institutions
  • Small and Medium Enterprises (SMEs)
  • State-owned Enterprises
Call Opening Date
22/06/2021
Call Closing Date
21/09/2021
National Contact Point(s)

Research and Innovation Foundation

Strovolos Avenue 123, 2042 Nicosia, Cyprus, P.O.Box 23422, 1683 Nicosia
Email: support@research.org.cy
Website: https://www.research.org.cy/

Dr Angelos Ntantos
Scientific Officer
Telephone: 35722205033
Email: antantos@research.org.cy

Dr Ioannis Theodorou

Scientific Officer
Telephone: 35722205038
Email: itheodorou@research.org.cy

(Publish Date: 05/08/2021-for internal use only)

 

Website
Funding&Tenders portal HE Main Work Programme 2021–2022 – 4. Health p. 151
This website uses cookies to improve your web experience.
Home
Account
Cart
Search
Explore
Drag